release interim cvac™ clinical data, page-3

And from the Ord Minnett Report -

"The key catalysts for the stock over the coming 12 months are likely to be related to trial results, with the next update expected in October 2012. The data will be in
relation to the 63 patient Phase IIb study (known as CAN-003), where preliminary efficacy data will be announced in conjunction with intracellular cytokine staining
(ICS) results, which will show whether CVac is producing the desired immune response. Good results would be a strong positive for the stock, in our view"

Things are looking quite spiffy I reckon